<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">4010</id>
  <title>T3D3956</title>
  <common-name>Cotinine</common-name>
  <description>Quantitatively, the most important metabolite of nicotine in most mammalian species is cotinine. In humans, about 70 to 80% of nicotine is converted to cotinine. This transformation involves two steps. The first is mediated by a cytochrome P450 system (mainly CYP2A6 and CYP2B6) to produce nicotine iminium ion. The second step is catalyzed by aldehyde oxidase (AOX). A number of cotinine metabolites have also been structurally characterized. Indeed, it appears that most of the reported urinary metabolites of nicotine are derived from cotinine.</description>
  <cas>486-56-6</cas>
  <pubchem-id>408</pubchem-id>
  <chemical-formula>C10H12N2O</chemical-formula>
  <weight nil="true"/>
  <appearance>White powder.</appearance>
  <melting-point>41°C</melting-point>
  <boiling-point></boiling-point>
  <density nil="true"/>
  <solubility></solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure>Inhalation</route-of-exposure>
  <target nil="true"/>
  <mechanism-of-toxicity></mechanism-of-toxicity>
  <metabolism>Cotinine is a metabolite of nicotine. Cotinine has an in vivo half-life of approximately 20 hours, and is typically detectable for several days (up to one week) after the use of tobacco. The level of cotinine in the blood is proportionate to the amount of exposure to tobacco smoke, so it is a valuable indicator of tobacco smoke exposure, including secondary (passive) smoke. People who smoke menthol cigarettes may retain cotinine in the blood for a longer period because menthol can compete with enzymatic metabolism of cotinine. (Wikipedia)</metabolism>
  <toxicity></toxicity>
  <lethaldose></lethaldose>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>Cotinine is an alkaloid found in tobacco and is also a metabolite of nicotine. (Wikipedia)</use-source>
  <min-risk-level></min-risk-level>
  <health-effects>Similarly to nicotine, cotinine binds to, activates, and desensitizes neuronal nicotinic acetylcholine receptors, though at much lower potency in comparison. It has demonstrated nootropic and antipsychotic-like effects in animal models. Direct administration of high levels of cotinine resulted in no significant physiologic, subjective, or performance effects. (Wikipedia)</health-effects>
  <symptoms></symptoms>
  <treatment></treatment>
  <created-at type="dateTime">2014-08-29T04:47:10Z</created-at>
  <updated-at type="dateTime">2026-03-31T18:51:03Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>Cotinine</wikipedia>
  <uniprot-id></uniprot-id>
  <kegg-compound-id></kegg-compound-id>
  <omim-id></omim-id>
  <chebi-id>127762</chebi-id>
  <biocyc-id>CPD-2742</biocyc-id>
  <ctd-id></ctd-id>
  <stitch-id></stitch-id>
  <drugbank-id></drugbank-id>
  <pdb-id></pdb-id>
  <actor-id></actor-id>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>CN1C(CCC1=O)C1=CN=CC=C1</moldb-smiles>
  <moldb-formula>C10H12N2O</moldb-formula>
  <moldb-inchi>InChI=1S/C10H12N2O/c1-12-9(4-5-10(12)13)8-3-2-6-11-7-8/h2-3,6-7,9H,4-5H2,1H3</moldb-inchi>
  <moldb-inchikey>UIKROCXWUNQSPJ-UHFFFAOYSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">176.2151</moldb-average-mass>
  <moldb-mono-mass type="decimal">176.094963016</moldb-mono-mass>
  <origin>Endogenous</origin>
  <state>Solid</state>
  <logp>0.07</logp>
  <hmdb-id>HMDB01046</hmdb-id>
  <chembl-id>CHEMBL664</chembl-id>
  <chemspider-id>395</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>Rolf, David; Goon, David J. W.; Michelson, Robert H.  Preparation of cotinine by reacting nicotine with bromide and bromate.    U.S.  (1997),     5 pp. </synthesis-reference>
  <structure-image-caption nil="true"/>
  <chemdb-id>CHEM002916</chemdb-id>
  <dsstox-id>DTXSID1047576</dsstox-id>
  <toxcast-id nil="true"/>
  <stoff-ident-origin nil="true"/>
  <stoff-ident-id nil="true"/>
  <susdat-id>NS00010263</susdat-id>
  <iupac nil="true"/>
  <moldb-polar-surface-area>33.2</moldb-polar-surface-area>
  <moldb-refractivity>49.2805</moldb-refractivity>
  <moldb-polarizability>18.57458933125395</moldb-polarizability>
  <moldb-rotatable-bond-count>1</moldb-rotatable-bond-count>
  <moldb-acceptor-count>2</moldb-acceptor-count>
  <moldb-donor-count>0</moldb-donor-count>
  <moldb-pka-strongest-acidic nil="true"/>
  <moldb-pka-strongest-basic>4.789340020074378</moldb-pka-strongest-basic>
  <moldb-physiological-charge>0</moldb-physiological-charge>
  <moldb-number-of-rings>2</moldb-number-of-rings>
  <moldb-alogps-logp>0.39</moldb-alogps-logp>
  <moldb-alogps-logs>-0.18</moldb-alogps-logs>
  <moldb-alogps-solubility>1.17e+02 g/l</moldb-alogps-solubility>
</compound>
